Orthopaedic Arthroscopic Surgery International (OASI) Bioresearch Foundation, Milan, Italy.
Cornell University, Weill Medical College, New York Presbyterian Hospital/Queens, New York, New York, USA.
Am J Sports Med. 2019 Jun;47(7):1621-1628. doi: 10.1177/0363546519845362. Epub 2019 May 16.
Cell-based cartilage repair performed as a single-stage procedure is an important advancement in the treatment of full-thickness cartilage injury and has potential for widespread clinical use.
To investigate the long-term clinical outcomes of cartilage repair in the knee with a hyaluronic acid-based scaffold embedded with bone marrow aspirate concentrate (HA-BMAC) for the treatment of full-thickness cartilage injury.
Case series; Level of evidence, 4.
Patients underwent treatment of full-thickness chondral injury in the knee with HA-BMAC and were followed prospectively for a minimum of 6 years. Clinical outcomes were examined with patient-reported scoring instruments that consisted of the Tegner Activity Scale, International Knee Documentation Committee (IKDC) subjective score, visual analog scale, and Knee injury and Osteoarthritis Outcome Score (KOOS). Comparative analysis of pre- and postoperative scores was performed, and the effects of patient age, body mass index, lesion size, number of treated lesions, and concurrent treatment with associated procedures were examined.
Twenty-three patients (mean age, 48.5 years) were followed prospectively for a mean 8 years (range, 6-10 years). Median cartilage lesion size was 6.5 cm (range, 2-27 cm). At final follow-up, median Tegner, visual analog scale, and IKDC subjective scores were 4, 0.3, and 85, respectively. Final median KOOS subset scores were as follows: Pain, 94; Symptoms, 89; Activities of Daily Living, 99; Sports/Recreation, 85; and Quality of Life, 85. All scores were significantly increased at final follow-up ( P < .001). Comparable median outcome scores were demonstrated after categorization of patients by age, lesion size, treatment of multiple lesions, treatment of multiple knee compartments, and treatment by associated procedures. Rank correlation analysis demonstrated a negative correlation between patient age and final outcome scores of the IKDC, Tegner, and KOOS subsets of Pain, Activities of Daily Living, and Sports/Recreation. No associations were identified between body mass index or lesion size and outcome scores.
Repair of full-thickness cartilage injury in the knee with a HA-BMAC provides good to excellent clinical outcomes at long-term follow-up in the treatment of small to large lesions. Cartilage repair with HA-BMAC leads to comparatively successful long-term outcomes in the treatment of small or large lesions, single or multiple lesions, and lesions in 1 or 2 compartments, as well as in cases of associated lesion treatment. While good outcomes can be expected among treated patients >45 years of age, outcomes may be comparatively more successful in younger patients.
作为一种单阶段手术的基于细胞的软骨修复是全层软骨损伤治疗的重要进展,具有广泛的临床应用潜力。
研究用于治疗全层软骨损伤的透明质酸(HA)-骨髓抽吸浓缩物(BMAC)支架的软骨修复的长期临床结果。
病例系列;证据水平,4 级。
对接受 HA-BMAC 治疗的全层软骨损伤患者进行前瞻性随访,随访时间至少 6 年。临床结果采用患者报告的评分量表进行评估,包括 Tegner 活动量表、国际膝关节文献委员会(IKDC)主观评分、视觉模拟评分和膝关节损伤和骨关节炎结果评分(KOOS)。对术前和术后评分进行比较分析,并检查患者年龄、体重指数、病变大小、治疗病变数量以及与相关手术同时治疗的影响。
23 例患者(平均年龄 48.5 岁)接受前瞻性随访,平均随访 8 年(范围 6-10 年)。中位软骨病变大小为 6.5cm(范围 2-27cm)。最终随访时,Tegner、视觉模拟评分和 IKDC 主观评分的中位数分别为 4、0.3 和 85。最终 KOOS 亚组评分中位数如下:疼痛,94;症状,89;日常生活活动,99;运动/娱乐,85;生活质量,85。所有评分在最终随访时均显著升高(P<0.001)。通过按年龄、病变大小、多个病变治疗、多个膝关节间隙治疗和相关手术治疗对患者进行分类,得出可比的中位结局评分。秩相关分析显示,患者年龄与 IKDC、Tegner 和 KOOS 亚组的疼痛、日常生活活动和运动/娱乐的最终结果评分呈负相关。体重指数或病变大小与结局评分之间未发现关联。
在治疗小至大病变时,使用 HA-BMAC 修复膝关节全层软骨损伤可获得良好至优秀的长期临床结果。在治疗小或大病变、单个或多个病变以及 1 个或 2 个间隙病变以及相关病变治疗时,HA-BMAC 引导的软骨修复可带来相对成功的长期结果。尽管可以预期治疗患者的年龄>45 岁时会有较好的结果,但在较年轻的患者中,结果可能更成功。